AFTAB ® is a drug based on Triamcinolone acetonide
THERAPEUTIC GROUP: Stomatological corticosteroid-based preparation for local oral treatment.
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications AFTAB ® Triamcinolone acetonide
AFTAB ® is indicated in the treatment of inflammatory and irritative diseases of the oral cavity such as aphthous ulcers, stomatitis, gingivitis and erosions.
Mechanism of action AFTAB ® Triamcinolone acetonide
AFTAB ® is a medicinal product based on Triamcinolone acetonide, an active ingredient belonging to the category of synthetic corticosteroids and therefore has a strong anti-inflammatory activity supported by the? Inhibition of? ™ enzyme activity phospholipase A2, responsible for the synthesis of arachidonic acid, starting substrate for the synthesis of inflammatory mediators.
The aforementioned activity, following the use of AFTAB ®, takes place only at the local level thanks to the presence of polymers that guarantee the adhesion of the tablet to the oral mucosa affected by the damaging process, thus allowing the topical release of Triamcinolone which takes the form of greater local efficacy and the absence of systemic side effects.
In addition to the classic and characterized anti-inflammatory action, Triamcinolone exerts on the spot an antipruritic activity which considerably reduces the annoyance classically associated with irritations of the pharyngeal gold mucosa.
Studies carried out and clinical efficacy
TRIAMCINOLONE AND ORAL LESIONS AND MAXILLO FACIALI
J Craniomaxillofac Surg. 2013 Jun; 41 (4): 345-9. doi: 10.1016 / j.jcms.2012.10.022. Epub 2012 Dec 17.
Study demonstrating that the addition of Triamcinolone to treatment with Pingiamycin may result in improved therapeutic efficacy in oral and maxillofacial lesions present during lymphatic malformations.
TRIAMCINOLONE AND LICHEN PLANUS
J Formos Med Assoc. 2013 Apr; 112 (4): 216-20. doi: 10.1016 / j.jfma.2012.01.014. Epub 2012 Apr 17.
Interesting work that demonstrates the effectiveness of the combination of local corticosteroids including Triamcinolone in ensuring prompt remission of lesions present during auto-inflammatory diseases such as lichen planus.
NEW DELIVERY SYSTEMS
Int J Pharm. 2013 May 22. pii: S0378-5173 (13) 00433-X.
Pharmacokinetic studies that continuously evaluate the efficacy of new polymers to be used for topical drug release, thus allowing to optimize the therapeutic role, considerably limiting the risk of potential systemic side effects.
Method of use and dosage
AFTAB ®
25 mg muco-adhesive buccal tablets Triamcinolone acetonide.
The correct therapeutic scheme involves the application of a buccal adhesive mucus tablet, in the area affected by the inflammatory process, once or twice a day, taking care to adhere the white layer of the same to the mucosa.
Treatment should not exceed 7 days without medical supervision, taking care not to swallow or chew the tablet.
Warnings AFTAB ® Triamcinolone acetonide
Due to the complexity of the tablet application, the use of AFTAB ® is generally contraindicated in children and in non-collaborative patients.
The use of topical Triamcinolone should be carefully evaluated in patients with obvious infections of the oral cavity, possibly preceding the aforementioned therapy with an appropriate antibiotic or fungicide.
It is advisable to read the package insert carefully so that the application of the adhesive mucus is done correctly.
PREGNANCY AND BREASTFEEDING
Given the absence of studies able to better characterize the safety profile of Triamcinolone acetonide for fetal health, it would be preferable to extend the aforementioned contraindications to the use of AFTAB ® also for pregnancy and the subsequent period of breastfeeding at otherwise.
Interactions
Drug interactions worthy of clinical note are currently unknown.
Contraindications AFTAB ® Triamcinolone acetonide
The use of AFTAB ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients during pregnancy and breastfeeding.
Undesirable effects - Side effects
The local anti-inflammatory action of Triamcinolone, reducing the defense capacity of the oral mucosa, could subject it to an increased risk of infections, especially those sustained by Candida albicans.
In this case the use of AFTAB ® should be suspended until the infection is completely resolved.
Fortunately, systemically relevant adverse reactions are clinically relevant.
Note
AFTAB ® is a non-prescription drug.
